Vyome Holdings, Inc

Vyome Holdings, Inc. announced its first fiscal quarter 2026 financial results, reporting approximately $8.8 million in cash and cash equivalents and a net loss of $963,000. The company significantly advanced its pipeline by signing an agreement with Impetis Biosciences Limited to in-license two selective JAK inhibitor assets, targeting a large global market. Additionally, Vyome made regulatory submissions to the FDA for Orphan Drug Designation status for its lead candidate VT-1953, which addresses malignant fungating wounds, and presented positive Phase 2 clinical data for VT-1953.

Vyome Holdings, Inc. reported a significant decrease in revenue and an increased net loss for the first quarter ended March 31, 2026. Revenue fell to $31,591 from $198,581 year-over-year, while net loss widened to $985,521 from $293,974. Despite the losses, the company's cash and cash equivalents increased to $8.8 million, largely due to $5.3 million from an At-The-Market (ATM) financing facility. Vyome continues to advance its clinical pipeline, with its lead program VT-1953 planning FDA discussions in Q2 2026 and VB-1953 being Phase III ready.

Vyome Holdings, Inc. held its 2026 Annual Meeting of Stockholders where shareholders approved a significant amendment to the Certificate of Incorporation. The authorized common stock was decreased from 300,000,000 to 50,000,000 shares, with the Certificate of Tenth Amendment filed to effectuate this change. Additionally, Venkat Nelabhotla and John Tincoff were elected as Class II directors, and the appointment of Kreit & Chiu CPA LLP as the independent auditor for fiscal year 2026 was ratified. Stockholders also approved executive compensation on an advisory basis.